Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities
Date
2013
Authors
Shao, H.
Shi, S.
Huang, S.
Hole, A.J.
Abbas, A.Y.
Baumli, S.
Liu, X.
Lam, F.
Foley, D.W.
Fischer, P.M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Medicinal Chemistry, 2013; 56(3):640-659
Statement of Responsibility
Conference Name
Abstract
Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death. CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells. We designed a series of 4-thiazol-2- anilinopyrimidine derivatives with functional groups attached to the C5-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity. One of the most selective compounds, 12u inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 versus CDK2. X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes. This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper,34 provides a rationale for the observed SAR. 12u demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal Band T-cells.
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supporting information, https://doi.org/10.1021/jm301475f
Access Status
Rights
Copyright 2013 American Chemical Society